Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Ascentage Pharma Group International - American Depository Shares (NQ:AAPG)

27.00 -0.88 (-3.16%)

Streaming Delayed Price Updated: 3:00 PM EST, Dec 26, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	3,599
Open	27.00
Bid (Size)	26.80 (400)
Ask (Size)	27.68 (300)
Prev. Close	27.88
Today's Range	27.00 - 27.19
52wk Range	17.00 - 48.45
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

This Hasbro Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

November 10, 2025

Via Benzinga

This Docebo Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Wednesday ↗

November 05, 2025

Via Benzinga

Performance

YTD	+56.5%	+56.5%
1 Month	-16.6%	-16.6%
3 Month	-28.6%	-28.6%
6 Month	-33.8%	-33.8%
1 Year	+56.5%	+56.5%

More News

Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday ↗

August 25, 2025

Via Benzinga

Earnings Scheduled For August 20, 2025 ↗

August 20, 2025

Via Benzinga

US Stocks Likely To Open Mixed As Trump Issues Tariff Letters: Experts Peg AI Investments As 'Durable Drivers Of Returns' ↗

July 08, 2025

Via Benzinga

Penguin Solutions, Merit Medical Systems And 3 Stocks To Watch Heading Into Tuesday ↗

July 08, 2025

Via Benzinga

Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance

July 07, 2025

From ASCENTAGE PHARMA GROUP INTERNATIONAL

Via GlobeNewswire

Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors

June 02, 2025

From ASCENTAGE PHARMA GROUP INTERNATIONAL

Via GlobeNewswire

Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report

June 02, 2025

From ASCENTAGE PHARMA GROUP INTERNATIONAL

Via GlobeNewswire

PDD Holdings Posts Weak Results, Joins EHang Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

May 27, 2025

Via Benzinga

Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025

May 22, 2025

From ASCENTAGE PHARMA GROUP INTERNATIONAL

Via GlobeNewswire

Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax

April 28, 2025

From ASCENTAGE PHARMA GROUP INTERNATIONAL

Via GlobeNewswire

Bitdeer Tech And Tempus AI Are Among Top 18 Mid-Cap Gainers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio? ↗

April 27, 2025

Via Benzinga

Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin

April 23, 2025

From ASCENTAGE PHARMA GROUP INTERNATIONAL

Via GlobeNewswire

Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines

April 21, 2025

From ASCENTAGE PHARMA GROUP INTERNATIONAL

Via GlobeNewswire

Argan Posts Upbeat Results, Joins KULR Technology, Abacus Global Management, W. R. Berkley And Other Big Stocks Moving Higher On Friday ↗

March 28, 2025

Via Benzinga

Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan ↗

March 27, 2025

Via Benzinga

Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results and Business Updates

March 27, 2025

From ASCENTAGE PHARMA GROUP INTERNATIONAL

Via GlobeNewswire

Earnings Scheduled For March 27, 2025 ↗

March 27, 2025

Via Benzinga

Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025

March 25, 2025

From ASCENTAGE PHARMA GROUP INTERNATIONAL

Via GlobeNewswire

Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025

March 12, 2025

From ASCENTAGE PHARMA GROUP INTERNATIONAL

Via GlobeNewswire

IPO Momentum Builds In 2025: Diginex, CTRL Group, And Others Post Strong Gains ↗

March 10, 2025

Via Benzinga

Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

March 05, 2025

From ASCENTAGE PHARMA GROUP INTERNATIONAL

Via GlobeNewswire

Ascentage Pharma Announces Partial Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

February 07, 2025

From ASCENTAGE PHARMA GROUP INTERNATIONAL

Via GlobeNewswire

Ascentage Pharma Announces Closing of U.S. Initial Public Offering

January 28, 2025

From ASCENTAGE PHARMA GROUP INTERNATIONAL

Via GlobeNewswire

Frequently Asked Questions

Is Ascentage Pharma Group International - American Depository Shares publicly traded?

Yes, Ascentage Pharma Group International - American Depository Shares is publicly traded.

What exchange does Ascentage Pharma Group International - American Depository Shares trade on?

Ascentage Pharma Group International - American Depository Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Ascentage Pharma Group International - American Depository Shares?

The ticker symbol for Ascentage Pharma Group International - American Depository Shares is AAPG on the Nasdaq Stock Market

What is the current price of Ascentage Pharma Group International - American Depository Shares?

The current price of Ascentage Pharma Group International - American Depository Shares is 27.00

When was Ascentage Pharma Group International - American Depository Shares last traded?

The last trade of Ascentage Pharma Group International - American Depository Shares was at 12/26/25 03:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.